Prediction of the Answer to the Treatment by Biotherapies for Naive Spondyloarthritis Disease During 6 Months by Combinatorial Analysis of Serum Biomarkers

Trial Profile

Prediction of the Answer to the Treatment by Biotherapies for Naive Spondyloarthritis Disease During 6 Months by Combinatorial Analysis of Serum Biomarkers

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Jun 2018

At a glance

  • Drugs Etanercept (Primary)
  • Indications Ankylosing spondylitis
  • Focus Therapeutic Use
  • Acronyms PRESA
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 01 Jun 2018 Status changed from recruiting to completed.
    • 03 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top